To: software salesperson who wrote (2955 ) 10/23/2013 5:52:00 PM From: Biotech Jim Read Replies (1) | Respond to <"And our recently acquired JAK 1, 2 inhibitor Momelotinib has been successfully reformulated and we’re currently in discussions with regulatory authorities regarding the specifics of the myelofibrosis Phase 3 program."-4 -[2-[[4-(4-morpholinyl) phenyl] amino]-4 -pyrimidinyl] benzamide; N-(cyanopyrimidin-4-yl) benzamide, according to my sleuthing on the JAK1/2 inhibitor space. It has a CAS # as follows: 1056634-68-4.This compound is orange in color , and although Cytopia did not present data on its initial formulation in the clinic, I would bet that it was delivered to patients in a capsule to allow for the initial clinical studies to be adequately blinded. I do not know the metabolic stream or whether it is passed in the urine as a colored substance. ( I have had past experience with colored compound(s) and they are a pain in the axx for clinical trial blinding, especially if they excreted via the kidney as the unmetabolized drug substance, obviously.) I suspect Cytopia was most interested in Ph2 proof of concept and did not have the pharmaceutical sciences expertise to deal with formulating the compound in a pill form. ht tp://mpnforum.com/the-senyak-report-june-2013/ tspace.library.utoronto.ca .? I am not sure the above will open as the link provided, but if you google CYT-387 you should come up with the Michael Marit PhD thesis from the University of Toronto.
